EFNS guidelines on disease-specific CSF investigations
Florian Deisenhammer MD, MSc, Professor of Neurology, Clinical Department of Neurology, Innsbruck Medical University, Anichstrasse 35, 6020 Innsbruck, Austria (tel.: +43 512 504 24264; fax: +43 512 504 24266; e-mail: email@example.com).
We reviewed the literature for disease-specific markers in cerebrospinal fluid (CSF) and evaluated their diagnostic and prognostic relevance in neurological diseases. High tau protein in combination with low amyloid β levels has a high sensitivity (80%) and specificity (90%) for Alzheimer’s disease (AD) against normal aging and can predict conversion of mild cognitive impairment to AD. The detection of 14-3-3 has a high sensitivity (80–90%) and specificity (90%) for the diagnosis of CJD. Low or undetectable CSF hypocretin-1 (orexin-1) levels constitute a diagnostic biomarker for narcolepsy with cataplexy. Detection of beta-2-transferrin indicates CSF contamination in oto- and rhinorrhoe with a sensitivity of >79% at a specificity of 95% similar to the beta-trace protein (sensitivity >90%, specificity 100%). However, beta-trace protein is faster and cheaper to perform. Possible future biomarkers are: elevated levels of vascular endothelial growth factor are relatively sensitive (51–100%) and specific (73–100%) for leptomeningeal metastases from solid tumors and are associated with a poor prognosis in this condition. Elevated CSF neurofilament (Nf) levels probably reflect acute neuronal degeneration. The prognostic value of CSF Nf levels is highest in acute conditions such as subarachnoid hemorrhage, acute optic neuritis and neuromyelitis optica.
Investigation of the cerebrospinal fluid (CSF) in neurological diseases has a long history and a small number of molecules have become the standard repertoire in routine CSF work-up such as total protein, glucose, cell count and differentiation, as well as quantitative and qualitative detection of immunoglobulins . In recent years, the search for biomarkers – a characteristic that is objectively measured and evaluated as an indicator of normal biologic processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention, as defined by the Biomarkers Definition Working Group  – in body fluids including the CSF has increased substantially. In addition to the guidelines on routine CSF investigations  we wanted to evaluate newer CSF markers with respect to their disease specificity or prognostic relevance.
Tau protein, amyloid beta, 14-3-3 and myelin basic protein
PubMed was searched up to January 2008 for key words including ‘CSF’, ‘tau’, ‘amyloid’, ‘14-3-3’, ‘myelin basic protein’, and ‘mbp’, which yielded 1785 hits. Only papers in English and relating to adult clinical neurology were considered for further analysis.
A Medline search using the search terms cerebrospinal fluid (CSF), narcolepsy, sleep disorder, hypocretin and orexin was conducted. The search was limited to the time between 1 January 1980 and 1 May 2008. The key words were cross-referenced as follows: (‘cerebrospinal fluid’ or ‘CSF’) AND (‘hypocretin or orexin’) AND (‘narcolepsy OR sleep disorder OR cataplexy’). The search returned 73 documents. Abstracts which primarily did not deal with human sleep disorders, case reports, reviews, comments and original articles, which were not published in English, were excluded. The remaining 13 articles were further analyzed.
Beta 2 transferrin
(Cerebrospinal fluid OR CSF) and (beta 2 transferrin) and (otorrhea OR otorrhoea OR rhinorrhoea OR rhinorrhea) NOT beta trace resulted in 60 abstracts. Reviews and reports not dealing with diagnostic issues or with other fluids than CSF were excluded resulting in 42 articles.
Beta trace protein (prostaglandin D synthase)
(Beta-trace protein OR Prostaglandin D Synthase) and (otorrhea OR otorrhoea OR rhinorrhoea OR rhinorrhea) NOT beta 2 transferrin resulted in 16 abstracts.
Vascular endothelial growth factor
PubMed Search for (‘VEGF’ OR ‘vascular endothelial growth factor’) AND ‘CSF’; limits: 1980 until May 2008, Language German or English, reports on humans resulted in 51 Abstracts. Of those four reviews, 21 papers not related to diagnostic VEGF testing in CSF, and four pediatric reports were excluded. The remaining 22 papers were included for evaluation.
PubMed was searched up to January 2008 for key words including CSF, neurofilament (Nf), patients, which yielded 91 hits. Articles dealing with adult patients were included (children excluded). Articles excluded were: articles focussing on anti-Nf antibodies, serum analysis only, animal studies, reviews, case reports or method description rather than biomarker investigation in patients, animal studies and articles that were not in English.
Evidence was classified as class I–IV and recommendations as level A–C according to the scheme agreed for EFNS guidelines  with class I and level A being the strongest classes of evidence/recommendation.
In a conference held in March 2006, various potential CSF biomarkers and methods of detection were discussed by the members of the taskforce including CSF proteomics, markers of axonal damage focusing on different subsets of Nfs, neurotransmitters, autoantibodies, anti-neural antibodies, ferritin, Amyloid-β (Aβ), tau and hyperphosphorylated-tau, 14-3-3 protein, myelin basic protein, sulfatid, beta-2-transferrin, VEGF, and S-100. Of those, only the markers discussed below were felt to be relevant enough to receive further attention for the present report.
The Cochrane database and guideline papers of the American Academy of Neurology (AAN) were searched for all above topics. No relevant publication was found.
CSF markers recommended for use in clinical routine
Tau protein and amyloid-β peptide
Tau proteins are microtubule-associated proteins important for the maintenance of axonal microtubules. Hyperphosporylated tau (P-tau) is present in neuritic tangles in Alzheimer’s disease (AD). Amyloid-β (Aβ) peptides are derived from cleavage of the amyloid precursor protein by β- and γ-secretases, resulting in the Aβ1-40 and Aβ1-42 peptide fragments. Aβ1-42 has a strong tendency to aggregate, and is a major component of amyloid plaques in AD. Increased CSF concentrations of tau and P-tau and low CSF concentrations of Aβ1-42 are typical findings in AD, have been reviewed by a task force of the World Federation of Societies of Biological Psychiatry, and have been incorporated in the latest research criteria for the diagnosis of AD [4–7]. Tau proteins and Aβ peptides can be easily measured by commercially available sandwich ELISA, but Aβ measurements should be interpreted with some caution (see below).
At a specificity of 90%, the sensitivity for AD according to clinical criteria of the most commonly used tau immunoassay is approximately 80%, and the sensitivity of Aβ1-42 is 80–90% (class I) . The sensitivity for the diagnosis of AD of P-tau assays, based on immunoassays recognizing tau phosphorylated on different serine and threonine residues, is more variable (class II) [4,8,9]. The combination of tau and Aβ1-42 has been assessed in several studies, and has been found to give a high sensitivity and specificity against normal aging and psychiatric disorders, whereas the specificity against other diseases is lower (class II) [10,11]. Increases in tau and low Aβ1-42 concentrations are also found in stroke, trauma and other diseases with a neurodegenerative component (Table 1). However, at least for stroke, P-tau levels have been reported as being normal [12,13]. P-tau may provide better specificity against dementia with Lewy bodies and frontotemporal dementia, but the phosphorylation sites providing the best discrimination may differ from one disease to another [14–18]. Low concentrations of Aβ1-42 and dramatic increases in tau without a similarly strong increase in P-tau, is observed in CJD (class I) [19–27]. In contrast, tau and P-tau increase in parallel in variant CJD (class III) . The discrimination between different tau and Aβ isoforms in CSF may be useful for the discrimination between different disease processes, but larger studies are needed to address this in detail [29–33].
Table 1. Summary of studies of total tau and amyloid β1-42 (Aβ1-42) peptide in cerebrospinal fluid in diseases other than Alzheimer dementia
|Multiple sclerosis (MS)|
| Increase in tau and P-tau in MS||Class II||[62,169–172]|
| Normal tau in most MS patients||Class II|||
|Dementia with Lewy bodies (LBD)|
| Lower Aβ1-42 in LBD||Class II||[10,174] |
| Increase in tau in LBD||Class III||[175,176]|
| Normal tau and Aβ1-42 in LBD||Class II|||
| Lower Aβ1-42 and increased tau in LBD||Class II||[178,179]|
|Semantic dementia (SD)|
| Increase in tau in SD||Class III|||
|Frontotemporal dementia (FD)|
| Increase in tau in FD||Class III||[175,176]|
| Increase in tau in FD||Class II|||
| Increase in tau, decrease in Aβ1-42||Class II|||
| Low Aβ1-42 in FD||Class III|||
|Parkinson disease (PD)|
| Lower Aβ1-42 to Aβ1-37 ratio in PD with dementia||Class III|||
| Normal Aβ1-42 in PD||Class II|||
| Lower Aβ1-42 and higher tau in PD with dementia, intermediate values in PD||Class II|||
| Low Aβ1-42 in PD||Class III|||
|Multiple system atrophy (MSA)|
| Higher tau in MSA than in PD||Class II|||
| Higher tau in MSA than in idiopathic cerebellar ataxia||Class II|||
| Low Aβ1-42 in MSA||Class II|||
|Corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP)|
| Higher tau in CBD than in PSP||Class II||[176,188]|
| Normal Aβ1-42 in PSP||Class II|||
| Low Aβ1-42 in CBD and PSP||Class III|||
|Vascular dementia (VD) and stroke|
| Increase in tau in VD||Class II|||
| Increase in tau in stroke||Class II|||
| Increase in tau, low Aβ1-42 and normal P181-tau in VD||Class II||[13,190]|
| Increase in tau, normal Aβ1-42 and normal P181-tau in VD||Class II|||
| Increased tau in amyotrophic lateral sclerosis||Class II|||
| Low Aβ1-42 in ALS||Class III|||
| Increased tau in Guillain-Barré syndrome, correlation with prognosis||Class II|||
|AIDS–dementia complex (ADC)|
| Low Aβ1-42 and high tau in ADC||Class II|||
| Increased tau in head injury||Class III||[193,194]|
| Decresed Aβ1-42 in head injury||Class III||[193,195]|
|Normal pressure hydrocephalus (NPH)|
| Low tau, P-tau and Aβ1-42 in NPH||Class II|||
| Increased tau in NPH||Class III||[176,197]|
A special indication for CSF studies is the identification of patients with mild cognitive impairment with CSF findings typical of AD , as there is class I evidence that such patients may be at increased risk of progression to AD [34–43]. When interpreting the results of Aβ1-42 measurements, it should be taken into account that concentrations may decrease following glucocorticoid treatment (class III)  and show pronounced diurnal fluctuations , and erroneously low values of Aβ1-42 are found if the CSF is not sampled and handled optimally [46–48]. Indeed, freezing and prolonged storage impairs the discriminatory value of ELISA measurements of Aβ . Furthermore, age-dependent reference values should be used for tau measurements, whereas Aβ1-42 values are independent of age. In one study, the reference value for Aβ1-42 was above 500 ng/l; for tau the reference value was <300 ng/l in patients from 21 to 50 years of age, <450 ng/l from 51 to 70 years of age, and <500 ng/l from 71 to 93 years of age .
In studies assessing the sensitivity and specificity of CSF markers for AD, the diagnosis has not been confirmed neuropathologically. Aβ1-42 values should be interpreted with some caution. There is, however, evidence that tau, p-tau and Aβ1-42 measurements have high sensitivity and specificity for discriminating AD against normal aging, and may identify patients with mild cognitive impairment at an increased risk of progression to AD (level A rating). The latter finding is of clear importance if therapies affecting the disease course of AD become available in the future.
14-3-3 is a ubiquitous protein with the highest concentrations found in brain . Mostly, it is determined qualitatively by western blot techniques, although a quantitative ELISA method is available. An initial study showed the presence of 14-3-3 in CSF from 96% of 71 patients with Creutzfeldt-Jakob disease (CJD) (class II) . In a prospective study including 805 patients with neuropathologically confirmed CJD the sensitivity of a positive 14-3-3 test was 94%, the specificity was 84%, and the 14-3-3 test was superior to EEG studies (class I) . High sensitivity and specificity of 14-3-3 has also been found in other studies (class I) [54–58]. Increases in 14-3-3 protein are less frequent in new variant CJD (class III) , in familial forms of spongiform encephalopathies and in infrequent subtypes of CJD (class III) [56,60,61]. Furthermore, increases in 14-3-3 protein are less frequent early and late in the course of sporadic CJD and early in the course of iatrogenic (growth hormone-induced) CJD (class III) [14,43,62]. Positive results of the 14-3-3 test have also been reported in other dementias, cerebrovascular disease, metabolic and hypoxic encephalopathies, brain metastases and CNS infections (class III) [27,27,52,55,58,63,64]. The detection of 14-3-3 in CSF has been reported to indicate a poor prognosis in patients with transverse myelitis, clinically isolated syndromes suggestive of MS and MS (class II) [65–67]; another study did not confirm these findings (class III) .
The detection of 14-3-3 has been reported to have a high sensitivity (94%) and specificity (84%) for the diagnosis of CJD in patients with clinical findings suggestive of this disease, but 14-3-3 can also be detected in CSF from patients with more common diseases (level A rating).
Hypocretin-1 (orexin-1) levels in narcolepsy
Human narcolepsy is a sleep disorder which affects up to 0.5% of the population. It is characterized by hypersomnia, cataplexia, sleep paralysis and hypnagogic hallucinations . The full spectrum of symptoms occurs only in a minority of patients. The disease is strongly associated with the HLA allele DQB1*0602. Based on animal models it is believed that narcolepsy is caused by a dysfunction of the hypocretin-1 (orexin-1) neurotransmitter system in the posterior and lateral hypothalamus. In human narcolepsy CSF hypocretin-1 (orexin-1) levels were reported to be low or absent. Thirteen studies were used to evaluate the role of CSF hypocretin-1 (orexin-1) in sleep disorders. Three studies were excluded from the analysis because of low patient numbers or lack of control groups [70–72]. The study Mignot et al. included patients from two previous studies, which were therefore also excluded from the analysis [73,74]. In all studies hypocretin-1 (orexin-1) levels in CSF were measured by radio immunoassay (RIA). Cut-off points ranged from 202 to 110 pg/ml. In most patients with narcolepsy with cataplexy orexin/hypocretin concentrations were low (sensitivities between 66% and 100%), in the majority of patients even below the detection limit of 40 pg/ml of the RIA (Table 2). This was in particular true for patients with HLA DQB1*0602 status . Low levels of hypocretin-1 (orexin-1) were also found in a minority of narcolepsy without cataplexy patients and other neurological disease (specificities between 92% and 100%) .
Table 2. Summary of the results from hypcretin-1/orexin-1 levels in narcolepsy
|69.3%d (137)||14.3% (21)||1.7% (228)||0% (47)e||110||IIIf|||
|91.7% (48)||40% (15)||0% (10)||0% (50)g||110||II|||
|81.8 (9)||0% (5)||8.3% (12)||nd||194||III|||
|70.6% (17)||0% (9)||nd||0% (15)h||200||IV|||
|100% (14)||100% (10)||0% (24)g||nd||100||IV|||
|88.5% (26)||11.1% (9)||0% (103)||nd||110||II|||
|66.0% (47)||0% (7)||0%i (10)||nd||209 pg/dl||II|||
Based on three class II and several class III and IV studies, hypocretin-1 (orexin-1) levels of <110 pg/ml in CSF can be classified as a diagnostic biomarker for narcolepsy with cataplexy (level A recommendation, in compliance with the International Classification of Sleep Disorders). The value of measuring hypocretin-1 (orexin-1) in CSF of other sleep disorders is controversial.
Transferrin is a polypeptide of the ß-globulin family, which is involved in ferrous ion transport. Beta-2-transferrin (synonyms: asialotransferrin, tau-fraction) is a transferrin form, without sialic acid side chains. In healthy human beings beta-2-transferrin has only been demonstrated in CSF, perilymph and aqueous humor of the eye, but not in serum [76,77]. In patients with chronic liver diseases [78,79], inborn error of glycoprotein metabolism  and persons with a genetic variant of transferrin [78,81,82] beta-2-transferrin can be also found in the blood.
Due to shortcomings of earlier methods (high resolution electrophoresis) [83,84] an isoelectric pH-focusing method was developed followed by immunofixation and silver staining, for which as little as 5 μg total protein is necessary (class III). Various sources of error in use of beta-2-transferrin analysis for diagnosing cerebral spinal fluid leaks were described , such as transferrin isoforms especially in saliva with electrophoretic mobility similar to that of beta-2-transferrin (class IV) .
In combination with other methods like high resolution computed tomography the detection of beta-2-transferrin in CSF contaminated nasal discharges and blood was able to confirm oto- and rhinorrhoe of different etiologies [83,84,87–94] (all class III, except one class IV) and used to monitor patients after surgical reconstruction of the frontal skull base (class III) . The test sensitivity varied between 79% and 100% (class III) [94,96,97] at a specificity of about 95% (class III) . Venous blood sampled at the same time as CSF may exclude false positive results due to inborn errors of glycoprotein metabolism, genetic variants of transferrin or chronic liver disease (class IV) [81,92].
Measurement of beta-2-transferrin in combination with computed tomography of the scull detects CSF contamination in oto- and rhinorrhoea with high sensitivity (79–100%) at a specificity of 95% (level B recommendation).
Beta-trace protein, ß-TP (prostaglandin D synthase, PGDS)
ß-TP (molecular mass, 25 kDa) is one of the most abundant locally synthesized proteins in the CSF [98,99]. Based on amino acid sequencing, it has been identified as prostaglandin D synthase (PGDS) which is a member of the lipocalin superfamily composed of various secretory lipophilic ligand-carrier proteins . Within the central nervous system, ß-TP has been localized by immunohistochemistry and in situ hybridization mainly in choroid plexus and leptomeninges . Concentrations of ß-TP in CSF ranged between 8 and 40 mg/l (age-dependent) and between 0.4 and 1.5 mg/l in serum. Because of its relatively high CSF concentration ß-TP has been explored for the diagnosis of oto- and rhinoliquorrhea [102–104].
For quantitative nephelometric analysis, a sample volume of at least 5 μl is needed which is diluted with a dilution buffer to a total volume of 500 μl. The detection range of the assay is between 0.25 and 15.8 mg/l, the detection limit is at 2.5 mg/l. The test requires <15 min having the advantage of intraoperative use and repeated frequent testing, e.g. evaluation of treatment success of CSF fistula repair .
Highest sensitivities and specificities as well as accuracy values were reported using a cut-off value of 1.31–6 mg/l [103,106,107] (Table 3, twice class II, one class III study). In addition, a secretion/serum ratio of ß-TP has been introduced with a normal range below 1.57 yielding 100% specificity . A cut-point at 1.11 mg/l for beta-trace protein gave the best trade-off between high sensitivity and high specificity when including the secretion/serum ratio . In direct comparison to beta-2-transferrin the sensitivity and specificity values to detect CSF contamination in oto- and rhinorrhoea were similar (class II) [102,103].
Table 3. Different cut-off values have been evaluated for diagnostic accuracy of CSF fistula (beta-trace protein)
n = 33
|0.9 n = 107||0.5 n = 34||11.1 n = 20||II|||
|Not reported||Not reported||>0.35|
n = 20
|0.016 (0.0–0.12) n = 29||0.6 (0.38–0–86) n = 132||18.4 (9.4–29.2) n = 132||III|||
(n = 53)
|0.4 (0.22–1.69) n = 160||0.6 (0.12–1.44) n = 116||19.6 (11.5–32.6) n = 19||II|||
A limitation of the ß-TP assay is that in patients with renal insufficiency and bacterial meningitis levels may substantially increase in serum and decrease in CSF, respectively. Hence, its use in such instances should be associated with cautious interpretation of the results.
The ß-TP test allows a quantitative detection of CSF fistulas with a high sensitivity and specificity (level A recommendation) in combination with computed tomography and clinical investigations. Due to procedural advantages ß-TP should be used as first line method depending on the frequency of requests (good practice point).
CSF markers with a future potential to be used in clinical routine
Vascular endothelial growth factor
Vascular endothelial growth factor (VEGF) is a glycosylated homodimeric protein of approximately 45 kDa. It is produced by a broad range of cell types in response to stimuli such as hypoxia or tumor necrosis factor (TNF)-alpha [109–113]. VEGF is selectively mitogenic for endothelial cells and plays a fundamental role in both normal and abnormal angiogenesis . VEGF can be measured with several commercially available sandwich enzyme-linked immunosorbent assays. Because those tests use various capture reagents, the resulting ‘normal’ ranges of VEGF in CSF depend on the test used.
Vascular endothelial growth factor in CSF was suggested to determine prognosis in several malignancies. VEGF was negatively correlated with survival in patients with leptomeningeal metastases [115,116] (class II), and astrocytic brain tumors [117,118] (class III). Furthermore, it serves as a biologic marker for the diagnosis and evaluation of treatment response in leptomeningeal metastases  (class III) (Table 4). VEGF is not detectable in lower grade gliomas (grade 2)  (class III).
Table 4. Vascular endothelial growth factor diagnostic sensitivity and specificity in leptomeningeal metastases
|100% (n = 19)||73%||(log tPA index–0.7229 * log VEGF index) < –0.18182||ELISA/121,165|| |||
|85% (n = 53)||100%||>262 ng/ml||ELISA||II|||
|73% (n = 37) 51%||93% 98.3%||>100 ng/ml >250 ng/ml||ELISA/121,165||II|||
|100% (n = 11)||100%||>633.1 ng/ml||ELISA/121,165||III|||
Studies investigating CSF VEGF in a number of other neurological conditions are summarized in Table 5 demonstrating a possible role in the pathogenesis of some diseases as well as some inconsistent findings.
Table 5. VEGF levels in studies not investigating leptomeningeal metastases
| Tuberculous (48)b||106c–144c||Various other forms of meningitis||5.7–80.1||ELISA/121, 165||II||[206,207]|
| Eosinophilic (9)||568||None|| ||ELISA/165||IV|||
| Pneumococcal (10)||Below lodd||Viral meningitis (10) non-inflammatory controls (10)||Slightly elevated below lod||Protein array||III|||
| Cryptococcal (95)||37.5c (geometric mean)||Spinal anesthesia (17)||Below lod||ELISA/121,165||2|||
| Any bacterial (37)||30% above cut-point (25 pg/ml)c||Viral meningitis (16) |
Non-inflammatory controls (35)
|HIV with CNS infection (8)||49.7||HIV negative CNS infection (18)||43.7||ELISA||III|||
|HIV without CNS infection (19)||42.6|
|CNS glioma grade 2 (7)||Below lod||Controls unspecified (3)||Below lod||ELISA||III|||
|CNS glioma grade 1 and 2 (7) |
CNS glioma grade 3 and 4 (19)
|Median 7.2 ng/ml|
|Hydrocephalus (10)||Median 8.3 ng/ml||ELISA||Uncertaine|||
|CNS glioma grade 3 and 4 (27)||4.9 ng/mg of total protein||Various tumors (31)||0.006 ng/mg of total protein||Not stated||IV|||
|Amyotrophic lateral sclerosis (105)b||Various ways of expressing VEGF levels (pg/ml, pg/l, int. Units)||Various groups including ‘neurological’ controls, neurodegenerative disorders, headache, radiculopathies, total n = 124||Ranging from significantly lower to equal to higher||ELISA/165||All class|
|Pre-eclampsia (15)||6.6||Pregnant normal pressure||5.5||ELISA||III|||
|Alzheimer disease (43)b||Below lod |
500c (only versus vasc. dementia)
|‘Healthy’controls (27) |
Vascular dementia (26)
‘Healthy’ controls (27)
|Below lod |
|SAH (14) |
|Non-SAH and ‘healthy’ controls (14) |
|POEMS syndrome (10)||6.8||Other neurological disease, GBS, CIDP (total 40)||3.0–9.1||ELISA||III|||
Elevated VEGF levels (cut-points between 100 and 650 pg/ml) in CSF are highly sensitive (73–100%) and specific (73–100%) for leptomeningeal metastases from solid but not from hematological tumors (level A recommendation) and are associated with a poor prognosis in this condition (level B recommendation). CSF VEGF levels appear to correlate with the grade of malignancy of CNS gliomas (level C recommendation). Normal to elevated as well as decreased VEGF in CSF can be found in various neurological diseases (bacterial meningitis, ALS, POEMS, and SAH) suggesting a possible pathogenic role without relevant diagnostic or prognostic value (level B recommendation).
Neurofilaments (Nfs) constitute the axonal cytoskeleton . There are four Nf subunits: a light (NfL, 68 kDa), intermediate (NfM, 115 kDa) and heavy chain (NfH, 190–210 kDa) and also alpha-internexin. NFs are released into the CSF following axonal damage. The normal upper reference rages for CSF NfH and NfL levels are presented in Table 6.
Table 6. Conditions in which increased NF has been shown
|Cut-off value||0.73 ng/ml ||Based on a reference population from a neurologial hospital (n = 416)|| || ||Rosengren: 125 pg/l; <60 years: <0.25 ng/ml; 60–70: 0.38 ng/ml; 71–80: <0.75 ng/ml; Norgren: 100 ng/l. Van Geel: 40 ng/l ||Population based reference values (healthy volunteers)|| || || |
|Condition in which neurofilament is increased|
| ALS||[122,135,137]||Five times higher than in controls. In upper motor symptoms two times higher than in lower motor symptoms||At cut-off of 0.73: 80% for ALS versus control. ALS versus AD: 80||75% (ALS versus control) ALS versus AD: 97%||[127,136,224]||About 10 times increase in patients with upper motor symptoms. About two times increase in patients with lower motor symptoms||n.a.||n.a.||Class II|
| PD & MSA||[143,145]||About 3 times elevated in MSA, not elevated in IPD||NfH: cut-off of 114.5: 83% for MSA-P versus IPD 77% for PSP from IPD (cut-off of 1.4 ng/ml)||87% for MSA versus IPD; 94% for PSP versus IPD||[144,145]||About seven times elevated in MSA, not elevated in IPD||NF-L: cut-off of 17.15: 83% for MSA-P versus IPD||90%||Class III|
| PSP||||The ROC optimised cut-off level of 1.48 ng/ml is used for distinguishing patients with PSP from those with PD or CBD||76.5%||93.8%||||n.a.||n.a.||n.a.||Class III|
| MS||In most MS patients CSF NfH levels are within the normal reference range .||At a cut-off: 160 pg/ml: sensitivity 34% and specificity 88% for conversion from CIS to RRMS . Contradictory results found by Lim . Relation with progression. Phophorylation rate eight times higher in severy disabled patients compared to mildly disabled patients  and also prognostic for deterioration at follow-up . NfH increases during follow-up ||n.a.||n.a.||[127,129,130] Not increased: ||2–10 times higher during relapses versus remission or SP [129,130]. R progr-index: 0.29 (P < 0.023) ||78% for MS; 91% for relapse, 44% for remission, 48% for SP||92–100%||Relation with progression: class II|
| AD||[225,226]||Using ROC optimised cut-off levels. NfH higher in AD compared to controls. Effect size 0.71 || 57.5%||77.0%||[127,228–230]||Increased in AD and VD compared to controls. In the meta-analysis the effect size distinguishing AD from controls was 1.27 with AD patients having the higher CSF NfL levels ||58–78%||28–77%||Class II|
| FTLD||[226,230]||NfH higher in FTLD compared to controls. Effect size 0.74  || || ||[226,228,230–232]||NfL Higher in FTLD compared to controls. Effect size was 1.38 ||82% to discriminate FTD from EAD in  contradictory with Pijnenburg et al.||70%||Class II|
| VD||||NfH is higher in VD then in AD||n.a.||n.a.||[127,228,229,233]||NfL Higher than in AD then in controls. Effect size 1.24 ||85%||68%||Class II|
| DLBD||||Using ROC optimised cut-off levels. NfH higher in DLBD compared to late AD||89%||28%|| ||Using ROC optimised cut-off levels. NfH higher in DLBD compared to late AD||33%||82%||Class III|
| Spinal cord injury ||n.d.|| || || ||||5 to 450x increased in acute cervical spine injury, and levels increase during 21 days after the injury||Cut-off of 125 ng/l, 100% sens for acute spinal cord injury, 18% for whiplash||100%||Class III|
| AIDS–dementia complex||n.d.|| || || ||[138–142]||n = 8, three subjects increased NF-L after interruption. Noclinical signs, but f.u. time only 101 days. Subclinical marker?||n.a.||86% ||Class II|
| SAH||[123–125]||Prognostic for outcome||Cut-off: highest value in survivors: 57–100% for unfavorable outcome||71–75%||[126–128]||Lumbar CSF||Cut-off for unfavorable outcome: 6,400 ng/l: 100% sens||50%||Class I|
| NPH||n.d.|| || || ||[196,235–237]||Ten times increased compared to reference values||n.a.||n.a.||Class III|
| Binswanger disease||n.d.|| || || ||||Four times increased compared to reference values.||n.a.||n.a.||Class III|
| GBS||||A prognostic marker for poor outcome. Not a diagnostic test||n.a.||n.a.||n.d.|| || || ||Class III|
| Cardiac arrest||n.d.|| || || ||||Prognostic for axonal damage after cardiac arrest||Poor outcome (Glasgow Coma Scale): 75–92%||80–100% for different cut-offs||Class III|
| HSV encephalitis relapse||n.d.|| || || ||||Higher during encephalitis relapse||n.a.||n.a.||Class III|
A comprehensive list of studies on NfL and NfH including cut-points and diagnostic sensitivity and specificity values is summarized in Table 6. Reference values depend on many pre-analytical and analytical factors and vary between laboratories. It is therefore, strongly encouraged that each laboratory establish its own reference values.
Neurofilaments are of prognostic value in subarachnoid hemorrhage (SAH). Increased levels of NfH and NfL in ventricular and lumbar CSF are related to poor outcome using the Glasgow outcome score (class I) [122–125] [126–128]. In MS, high CSF NfL levels were of prognostic value on a number of clinical outcome scales (class III) [129,130]. The heavy chain of Nfs in CSF was also related to progression within the subsequent year in RRMS patients (class III) [131–133]. Moreover, CSF NfH levels in the CSF or plasma of patients with optic neuritis (ON) predicted the degree of permanent loss of visual function (class III) [132,134]. Finally, CSF NfH levels were significantly higher in patients with neuromyelitis optica (NMO) which is consistent with the clinical experience of more severe disease and more extensive axonal loss in NMO than in MS (class III) .
In amyotrophic lateral sclerosis (ALS) patients high CSF NfH levels were related to a more rapid clinical progression and with upper motor neuron symptoms (class II) [136,137]. In the AIDS–dementia complex elevated CSF NfL levels were shown to be a good secondary outcome measure in an antiretroviral treatment trial (class III) [138–142]. CSF Nf levels could discriminate different Parkinsonian disorders. NfL and NfH levels were higher in patients with multi-system atrophy compared to patients with Parkinson’s disease (class II) [143–145].
A recent meta-analysis reviewing the value of CSF NfL and NfH in neurodegenerative dementia concluded that CSF NfL and NfH levels were increased in AD, frontotemporal lobar dementia (FTLD) and vascular dementia (class III) (see Table 6 for references and ). In comparison to CSF tau and Aβ1-42 levels the diagnostic accuracy of CSF NfL and NfH levels is lower.
Cerebrospinalfluid neurofilament levels can be used as a biomarker for neuronal death and axonal degeneration (level B rating). The prognostic value of CSF Nf levels is highest in acute conditions such as SAH, ALS, MSA, MS, acute ON and NMO (level B rating). There is further evidence from longitudinal studies that there is potential for CSF Nf to be used to monitor disease progression in SAH, MS and spinal cord injury (level B rating). Because reference values depend on many pre-analytical and analytical factors, laboratories should establish their own reference values.
Myelin basic protein
Myelin basic protein (MBP) is a major protein in CNS myelin, but constitutes a lesser proportion of myelin in the PNS . The CSF concentration of MBP increases with age (class I) , and many disease processes, even diseases affecting mainly peripheral nerve myelin, may show increases in the CSF concentration of MBP (class II) [148–151]. It is mostly measured by radioimmunoassay, but ELISA assays have also been developed. The CSF concentration of MBP is increased in multiple sclerosis (MS) (class I), where it is higher in relapses than in progression (class I), correlates with the severity of the relapse (class II), is higher in patients with multifocal relapses than in monofocal relapses (class III), and is higher in relapses with new symptoms than with the recurrence of previous symptoms (class III) [152,153–159]. Increased CSF concentrations of MBP in patients in clinical remission may be associated with an increased relapse risk and a lower risk of a benign disease course (class III) [160,161].
The CSF concentration of MBP decreases in parallel with spontaneous remission of clinical symptoms and with the resolution of active brain lesions on Gd-enhanced MRI after treatment with methylprednisolone (class III) [162,163]. Increased CSF concentrations of MBP may indicate a better short-term response to treatment with methylprednisolone, but Gd-enhanced MRI studies are superior to MBP measurements in this respect (class III) [164,165].
Myelin basic protein immunoassays are technically demanding because the analyte exists both in free and lipid-bound forms and bound in immune complexes. This is often not considered in CSF research. Increased CSF concentrations of MBP are unspecific and can be found in a variety of diseases, not only in MS (level A rating). It is possible that MBP measurements could be of prognostic value in MS (level C rating).
Recommendations for future research
In general, disease-specific biomarkers for diagnostic, prognostic, and monitoring purposes should be validated using established protocols [166,167]. Furthermore, validation across laboratories is urgently needed for many biomarkers, as shown for Aβ and Tau proteins . With respect to Aβ1-42, tau and P-tau, there is a need for evaluation of the precise predictive value of these methods in the differentiation between different neurodegenerative diseases, rather than as for the discrimination between healthy aging and patients with AD (incipient or definite). There seems to be a potential for assays recognizing different phosphoforms of tau in differential diagnosis, and this issue should be pursued in future studies.
Studies of 14-3-3 protein, Aβ1-42, tau and P-tau may also be helpful as diagnostic aids in patients with suspected CJD, but since CJD is a rare disorder, a very high diagnostic specificity against a wide spectrum of other diseases presenting with rapidly progressing dementia is necessary, and this issue needs to be investigated more thoroughly. The value of measuring hypocretin-1 (orexin-1) levels in CSF of other sleep disorders needs to be addressed. A serum marker for narcolepsy with cataplexy would be helpful for early diagnosis and serial analysis during the course and treatment of the disease.
The diagnostic and prognostic value of VEGF in leptomeningeal metastases should be confirmed in a larger prospective study, specifically in cytology-negative patients. For patients with leptomeningeal metastases from hematological tumors more sensitive markers need to be explored. Regarding the Nf assays, standardization of the assays and variation amongst different laboratories should be explored, in order to define reliable reference values. The use of Nfs in predicting neurological decline must be explored further. Further research should also focus on combining Nfs with other markers, as they will probably not be able to predict neurological decline with sufficient specificity and sensitivity as a stand alone marker.